HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Incyte Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Incyte Intelligence Report

Generated from 12 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Aug 4, 2026

Confidence

Moderate Confidence · 74%

Evidence

63 items

Sources

17

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Incyte maintains an active intelligence profile across Hematology, JAK Inhibitor, Oncology, Small Molecule, Dermatology. 12 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 74% across 3 tracked sources. Highest-priority development: FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer. Regulatory precedent. Why this matters: illustrates how regulators handled a comparable approval decision relevant to Incyte; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA TA — Ruxolitinib (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — JAKAFI XR (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    eCTD Submission Standards for eCTD v4.0 and Regional M1

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Data Standards Program Strategic Plan and Board

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — JAKAFI XR (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — ROSUVASTATIN CALCIUM (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA TA — Ruxolitinib (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    IND Application Reporting: IND Safety Reports

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 640 with buyer quality 10 (Enterprise). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA TA — Ruxolitinib (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — JAKAFI XR (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • eCTD Submission Standards for eCTD v4.0 and Regional M1

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Data Standards Program Strategic Plan and Board

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — JAKAFI XR (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ROSUVASTATIN CALCIUM (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA TA — Ruxolitinib (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • IND Application Reporting: IND Safety Reports

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Clinical trials for medicines: collection, verification and reporting of safety events

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • IND Application Reporting: IND Safety Reports

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Novartis initiates long-term safety study for ruxolitinib and panobinostat combination

    Hematology · JAK Inhibitor

  • FDA Approves JAKAFI XR (Ruxolitinib Phosphate) Submission by Incyte

    Hematology · JAK Inhibitor

  • FDA Submission for Ruxolitinib by Apotex Receives Standard Review Status

    Hematology · JAK Inhibitor

  • FDA Approves JAKAFI XR for Incyte Corp.

    Hematology · JAK Inhibitor

  • FDA Accepts Supplement for JAKAFI (Ruxolitinib Phosphate) by Incyte

    Hematology · JAK Inhibitor

  • FDA Accepts Supplement for ZYNYZ (Retifanlimab-Dlwr) by Incyte

    Oncology · Immunotherapy

  • Incyte's INCA33890 Safety Study in Advanced Solid Tumors Initiated

    Oncology · Small Molecule

  • Incyte's Ruxolitinib Cream Shows Promise for Pediatric Nonsegmental Vitiligo

    Dermatology · Nonsegmental Vitiligo

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.